ERBB2 and breast cancer: Crucially, integrating diverse data modalities enhances predictive accuracy and robustness, providing clinicians with insights for model selection in clinical scenarios, as shown in HER2‐positive breast cancer management where AI synthesizes histopathological, radiomics, and binding site data to guide therapy [107].